scholarly journals Trends in Q fever serologic testing by immunofluorescence from four large reference laboratories in the United States, 2012–2016

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Halie K. Miller ◽  
Alison M. Binder ◽  
Amy Peterson ◽  
Elitza S. Theel ◽  
Joseph M. Volpe ◽  
...  
2017 ◽  
Vol 1 (3) ◽  
pp. 156-160
Author(s):  
Jacqueline Watchmaker ◽  
Sean Legler ◽  
Dianne De Leon ◽  
Vanessa Pascoe ◽  
Robert Stavert

Background: Although considered a tropical disease, strongyloidiasis may be encountered in non-endemic regions, primarily amongst immigrants and travelers from endemic areas.  Chronic strongyloides infection may be under-detected owing to its non-specific cutaneous presentation and the low sensitivity of commonly used screening tools. Methods: 18 consecutive patients with serologic evidence of strongyloides infestation who presented to a single urban, academic dermatology clinic between September 2013 and October 2016 were retrospectively included.  Patient age, sex, country of origin, strongyloides serology titer, absolute eosinophil count, presenting cutaneous manifestations, and patient reported subjective outcome of pruritus after treatment were obtained via chart review.  Results: Of the 18 patients, all had non-specific pruritic dermatoses, 36% had documented eosinophila and none were originally from the United States. A majority reported subjective improvement in their symptoms after treatment. Conclusion:  Strongyloides infection and serologic testing should be considered in patients living in non-endemic regions presenting with pruritic dermatoses and with a history of exposure to an endemic area.Key Points:Chronic strongyloidiasis can be encountered in non-endemic areas and clinical manifestations are variableEosinophilia was not a reliable indicator of chronic infection in this case series Dermatologists should consider serologic testing for strongyloidiasis in patients with a history of exposure and unexplained pruritus


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S158-S158
Author(s):  
Eric C Stone ◽  
Zerelda Esquer Garrigos ◽  
Muhammad R Sohail ◽  
Raymund R Razonable ◽  
John C O’Horo

Abstract Background Demographic and epidemiologic characteristics of Hepatitis E virus (HEV) infected patients in the United States are not well-described. HEV infection may result in severe complications and lead to chronic infection and cirrhosis, especially in immunocompromised patients. There are no widely accepted guidelines for HEV screening and testing in the United States. Identifying traits of known seropositive patients and comorbidities may inform better screening and prevention strategies. In this study, we describe rates of liver disease, transplant status, chronic kidney diseases, and diabetes mellitus among patients serologically tested for HEV at our institution. Methods We retrospectively reviewed all patients for whom HEV IgM or IgG serologic testing was performed across the Mayo Clinic enterprise using the Advanced Cohort Explorer tool. For patients with any documented HEV serologic test, we abstracted baseline patient characteristics and underlying comorbidities at the time of testing. We then grouped subjects according to serologic testing results by antibody type. Survival at one year from date of testing was also assessed. Results A total of 979 unique subjects were identified. The preponderance of subjects was Caucasian (781, 79.8%). Of subjects tested for HEV with serology, 123 (12.6%) had any positive serology. Breakdown of baseline characteristics and selected comorbidities are summarized in Table 1. The largest proportion of subjects, 458 (46.8%), were both IgG and IgM negative and 432 subjects received only IgM or IgG testing. Liver disease was more prevalent in patients with positive vs. negative testing (5.8% vs. 2.1%) as was higher age (average 55.1 years vs. 52.2). One-year survival was similar in all groups. Conclusion HEV serology is not commonly tested. Among those tested, seropositivity is uncommon. Our data show higher HEV seropositivity in older adults, which may represent increase risk of exposure over time. Higher percentage of positive testing was also observed in subjects with liver disease, which may indicate a possible etiologic association. Further population-based studies are needed to estimate prevalence of HEV infection and associated liver disease, outcomes in infected patients, and indications for testing in at-risk populations. Disclosures All authors: No reported disclosures.


2002 ◽  
Vol 2 (3) ◽  
pp. 179-191 ◽  
Author(s):  
Jennifer H. McQuiston ◽  
James E. Childs

2014 ◽  
Vol 14 (2) ◽  
pp. 111-117 ◽  
Author(s):  
Adam Bjork ◽  
Nicola Marsden-Haug ◽  
Randall J. Nett ◽  
Gilbert J. Kersh ◽  
William Nicholson ◽  
...  

1948 ◽  
Vol 4 (3) ◽  
pp. 468
Author(s):  
Elias Strauss ◽  
S.Edward Sulkin ◽  
Elizabeth L. Watson

1979 ◽  
Vol 91 (3) ◽  
pp. 400 ◽  
Author(s):  
ROBERT C. KIMBROUGH

Sign in / Sign up

Export Citation Format

Share Document